Leukemia is a leading cause of
cancer death. Recently, the latexin (Lxn) gene was identified as a potential
tumor suppressor in several types of solid
tumors and
lymphoma, and Lxn expression was found to be absent or downregulated in leukemic cells. Whether Lxn functions as a
tumor suppressor in
leukemia and what molecular and cellular mechanisms are involved are unknown. In this study, the myeloid leukemogenic FDC-P1 cell line was used as a model system and Lxn was ectopically expressed in these cells. Using the
protein pull-down assay and mass spectrometry,
ribosomal protein subunit 3 (Rps3) was identified as a novel Lxn
binding protein. Ectopic expression of Lxn inhibited FDC-P1 growth in vitro. More surprisingly, Lxn enhanced gamma irradiation-induced
DNA damages and induced cell-cycle arrest and massive
necrosis, leading to depletion of FDC-P1 cells. Mechanistically, Lxn inhibited the nuclear translocation of Rps3 upon radiation, resulting in abnormal mitotic spindle formation and
chromosome instability. Rps3 knockdown increased the radiation sensitivity of FDC-P1, confirming that the mechanism of action of Lxn is mediated by Rps3 pathway. Moreover, Lxn enhanced the cytotoxicity of chemotherapeutic agent,
VP-16, on FDC-P1 cells. Our study suggests that Lxn itself not only suppresses leukemic cell growth but also potentiates the cytotoxic effect of radio- and
chemotherapy on
cancer cells. Lxn could be a novel molecular target that improves the efficacy of anti-
cancer therapy.